Progestin-induced heart and neural crest derivatives-expressed transcript 2 inhibits angiopoietin 2 via fibroblast growth factor 9 in human endometrial stromal cells

Hiromi Murata, Tomoko Tsuzuki, Takeharu Kido, Maiko Kakita-Kobayashi, Maiko Kakita‐Kobayashi, Naoko Kida, Yoji Hisamatsu, Hidetaka Okada
Reproductive biology · 2019 · vol. 19(1) , pp. 14–21 · doi:10.1016/j.repbio.2019.02.005 · PMID:30852242 · W2921646001
Lab / animal OA: closed CC0 ⤵ 1 in-corpus citation
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study investigated how progestin-induced heart and neural crest derivatives-expressed transcript 2 (PAX2) inhibits angiopoietin 2 (ANGPT2) through fibroblast growth factor 9 (FGF9) in human endometrial stromal cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Heart and neural crest derivatives-expressed transcript 2 (HAND2) is a key transcription factor in progestin-induced decidualization of human endometrial stromal cells (ESCs). In the mouse, HAND2 plays an important role in uterine receptivity by suppressing several fibroblast growth factors (FGFs). However, the regulation of FGF family members by progestin-induced HAND2 and the role of FGF in vascular regeneration in the endometrium remains poorly understood. To investigate these molecular mechanisms, primary human ESCs were cultured with estradiol (E2), medroxyprogesterone acetate (MPA), progesterone receptor (PR) antagonist RU486, HAND2-specific small interfering RNA (siRNA), and recombinant FGF. The expression levels of FGF family members, HAND2, angiopoietin (ANGPT), and vascular endothelial growth factor (VEGF) were assessed by real-time PCR and ELISA. Out of six FGF genes known to be expressed in the human endometrium, only one, FGF9, was significantly downregulated in human ESCs after 3 days of progestin treatment. E2 + MPA attenuated the mRNA and protein levels of FGF9 during decidualization of ESCs, and this effect was blocked by RU486. Silencing of HAND2 significantly increased FGF9 expression in ESCs treated with E2 + MPA. Moreover, FGF9 activated FGF receptor in human ESCs, triggering ANGPT2 production, which resulted in enhancement of the ANGPT2/ANGPT1 protein ratio. Taken together, progestin-PR signaling and its target HAND2 play an essential role in FGF9 suppression in the human endometrium. In addition, progestin-induced HAND2 inhibits ANGPT2 production by suppressing FGF9 in ESCs. These results suggest that HAND2 may contribute to endometrial vascular maturation by regulating FGF9 during decidualization.

My notes (saved in your browser only)

MeSH descriptors

Angiopoietin-2 Basic Helix-Loop-Helix Proteins Fibroblast Growth Factor 9 Gene Expression Regulation Progestins Stromal Cells Angiopoietin-2 Angiopoietin-2 Basic Helix-Loop-Helix Proteins Basic Helix-Loop-Helix Proteins Endometrium Endometrium Estradiol Estradiol Female Fibroblast Growth Factor 9 Fibroblast Growth Factor 9 Gene Expression Regulation Humans Luteolytic Agents

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (43)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:24:09.876621+00:00
unpaywall
last seen: 2026-10-24T06:30:43.844863+00:00
License: CC0 · commercial use OK